Articles
Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift
Heart failure is a clinical syndrome responsible for at least one-third of hospitalisations amongst cardiac patients, with escalating mortality and healthcare costs on both public and private health care.
A recently developed pharmacotherapy that inhibits both the angiotensin receptor and the enzyme neprilysin has shown promise in the management of heart failure with reduced ejection fraction.
Click here to access the article.